Fibrobiologics Inc (FBLG) Stock Price, Quote & News

Company Profile

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It al...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 671 5150

Website: fibrobiologics.com

Address:

455 East Medical Center Boulevard, Suite 300, Houston, United States

ShangVXO Aug. 19 at 8:10 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $FBLG + $LZMH joining my portfolio

0 · Reply

Casualtradess Aug. 17 at 4:05 PM

$FBLG Pipeline includes psoriasis, MS, disc degeneration🔥.

0 · Reply

Enoch120 Aug. 14 at 2:34 PM

$FBLG Way to go Armistice Capital! Hoping more tutes show up tooting their way to profits!

1 · Reply

rayankhader Aug. 14 at 2:18 PM

$KUST $VVOS $AGRZ $FBLG $WNW 🏦💰🛒🛍️🛒🛒🛍️🛒🛒🛍️🤷🏻‍♂️💎👀

0 · Reply

rayankhader Aug. 13 at 6:00 PM

$FBLG 🤷🏻‍♂️🛒🛍️🛍️🛍️

0 · Reply

swapo1 Aug. 13 at 5:37 PM

$FBLG next up

0 · Reply

rayankhader Aug. 13 at 5:21 PM

$BIVI i gave it to you at $1.05 and $1.17 and it run hard $INHD give it you at $6.38 and $6.40 and ran to $9.75 and still running $FBLG $VVOS $WNW they will run next 🤷🏻‍♂️💰🛒👀💎🏦🏦🛍️

0 · Reply

rayankhader Aug. 13 at 5:05 PM

$INHD on fireeeeeeeeeeee 🏦🏦🏦🏦🏦🏦🏦 $WNW $VVOS $FBLG they will run hard 🤷🏻‍♂️💎🛒🛒💎💎💎💎💰🛍️🛍️💰💰🛒🏦💎💎💎

0 · Reply

STACKD0E Aug. 13 at 4:41 PM

$BGDE $QMLS $FBLG $RNXT 🙃✨️

0 · Reply

rayankhader Aug. 13 at 3:39 PM

$FBLG the big run coming

1 · Reply

FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints

2026-08-11T12:35:28.000Z - 8 days ago

FibroBiologics awarded new patent from USPTO

Aug 11, 2026, 8:30 AM EDT - 8 days ago

FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

2026-08-05T14:12:16.000Z - 14 days ago

FibroBiologics announces EPO granted patent for gene cartilage therapy

Aug 5, 2026, 8:30 AM EDT - 14 days ago

FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage

2026-08-04T10:00:32.000Z - 15 days ago

FibroBiologics price target lowered to $6 from $8 at H.C. Wainwright

Jul 31, 2026, 5:34 PM EDT - 18 days ago

FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate

Jul 31, 2026, 8:00 AM EDT - 19 days ago

FibroBiologics Proxy statement: Proxy filing

Jul 31, 2026, 7:00 AM EDT - 19 days ago

FibroBiologics Quarterly report: Q2 2026

Jul 31, 2026, 7:00 AM EDT - 19 days ago

FibroBiologics Earnings release: Q2 2026

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

FibroBiologics Proxy statement: Proxy filing

Jul 10, 2026, 8:00 AM EDT - 5 weeks ago

FibroBiologics Registration statement: Registration filing

2026-07-10T11:25:14.000Z - 5 weeks ago

FibroBiologics files to sell up to 12.53M shares of common stock

2026-07-09T12:41:41.000Z - 5 weeks ago

FibroBiologics appoints Rubins to its Board of Directors

Jul 9, 2026, 8:30 AM EDT - 5 weeks ago

FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors

2026-07-07T12:40:57.000Z - 6 weeks ago

FibroBiologics completes manufacturing of third batch of CYWC628

Jul 7, 2026, 8:30 AM EDT - 6 weeks ago

FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Jun 29, 2026, 4:01 PM EDT - 7 weeks ago

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

2026-06-26T12:40:14.000Z - 7 weeks ago

FibroBiologics announces $9M private placement priced at-the-market

Jun 26, 2026, 8:30 AM EDT - 7 weeks ago

FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 22, 2026, 12:00 PM EDT - 2 months ago

FibroBiologics Transcript: AGM 2026

2026-06-22T13:39:09.000Z - 2 months ago

FibroBiologics receives notice of allowance for U.S. patent

Jun 22, 2026, 8:30 AM EDT - 2 months ago

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

2026-06-16T12:58:52.000Z - 2 months ago

FibroBiologics doses first patients in CYWC628 clinical trial

Jun 16, 2026, 8:30 AM EDT - 2 months ago

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers

2026-06-03T12:30:49.000Z - 2 months ago

FibroBiologics doses first patients in CYWC628 trial

Jun 3, 2026, 7:00 AM EDT - 2 months ago

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

2026-05-22T12:45:44.000Z - 3 months ago

FibroBiologics presents preclinical data from CYPS317 program

May 22, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

May 18, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

2026-05-11T14:42:59.000Z - 3 months ago

FibroBiologics expands fibroblast-based platform to target Hantavirus

May 11, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 5, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics CEO Issues Letter to Shareholders

May 5, 2026, 8:00 AM EDT - 3 months ago

FibroBiologics Proxy statement: Proxy filing

May 5, 2026, 8:00 AM EDT - 3 months ago

FibroBiologics Proxy statement: Proxy filing

2026-05-04T21:05:51.000Z - 3 months ago

FibroBiologics says fibroblast spheroids drive burn healing, reduce scarring

May 4, 2026, 4:01 PM EDT - 3 months ago

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

2026-05-04T13:30:12.000Z - 3 months ago

FibroBiologics releases first batch of CYWC628 for Phase 1/2 trial

May 4, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

2026-05-04T12:28:08.000Z - 3 months ago

FibroBiologics downgraded to Hold from Buy at Maxim

2026-04-30T22:00:27.000Z - 3 months ago

FibroBiologics reports Q1 net loss roughly ($5M)

Apr 30, 2026, 5:55 PM EDT - 3 months ago

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

Apr 30, 2026, 8:30 AM EDT - 3 months ago

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

Apr 30, 2026, 7:00 AM EDT - 3 months ago

FibroBiologics Quarterly report: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 3 months ago

FibroBiologics Earnings release: Q1 2026

Apr 22, 2026, 8:00 AM EDT - 4 months ago

FibroBiologics Proxy statement: Proxy filing

2026-04-20T20:23:12.000Z - 4 months ago

FibroBiologics announces compliance with all Nasdaq listing requirements

Apr 20, 2026, 4:01 PM EDT - 4 months ago

FibroBiologics Compliant with All Nasdaq Listing Requirements

2026-04-16T14:53:32.000Z - 4 months ago

FibroBiologics target adjusted to $8 at H.C. Wainwright after reverse split

Apr 10, 2026, 8:30 AM EDT - 4 months ago

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

Apr 2, 2026, 4:01 PM EDT - 4 months ago

FibroBiologics Announces Closing of $3 Million Public Offering

2026-04-01T00:05:13.000Z - 5 months ago

FibroBiologics prices $3M public offering

Mar 31, 2026, 8:00 PM EDT - 5 months ago

FibroBiologics Announces Pricing of $3 Million Public Offering

Mar 31, 2026, 4:15 PM EDT - 5 months ago

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

Mar 27, 2026, 8:00 AM EDT - 5 months ago

FibroBiologics Registration statement: Registration filing

Mar 25, 2026, 4:30 PM EDT - 5 months ago

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement

Mar 12, 2026, 8:30 AM EDT - 5 months ago

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

$FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

Mar 5, 2026, 8:30 AM EST - 5 months ago

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Mar 2, 2026, 8:30 AM EST - 6 months ago

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

Feb 26, 2026, 8:30 AM EST - 6 months ago

FibroBiologics to Present at the BIO Investment & Growth Summit

Feb 24, 2026, 4:30 PM EST - 6 months ago

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 24, 2026, 7:00 AM EST - 6 months ago

FibroBiologics Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

FibroBiologics Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

FibroBiologics Annual report: Q4 2025

Feb 23, 2026, 8:30 AM EST - 6 months ago

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

Feb 20, 2026, 12:00 PM EST - 6 months ago

FibroBiologics Transcript: EGM 2026

Feb 10, 2026, 8:30 AM EST - 6 months ago

FibroBiologics' Chairman & CEO Pete O'Heeron Selected to Present at A4LI's H-SPAN Summit at Georgetown University

Feb 5, 2026, 8:30 AM EST - 6 months ago

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

Jan 20, 2026, 8:30 AM EST - 7 months ago

FibroBiologics to Present at the DealFlow Discovery Conference

Jan 6, 2026, 8:30 AM EST - 8 months ago

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

Jan 5, 2026, 8:30 AM EST - 8 months ago

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

Dec 31, 2025, 8:30 AM EST - 8 months ago

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Dec 29, 2025, 7:00 AM EST - 8 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 29, 2025, 7:00 AM EST - 8 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 23, 2025, 7:00 AM EST - 8 months ago

FibroBiologics Registration statement: Registration Filing

Dec 18, 2025, 7:00 AM EST - 8 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 18, 2025, 7:00 AM EST - 8 months ago

FibroBiologics Proxy statement: Proxy Filing

Dec 16, 2025, 4:05 PM EST - 8 months ago

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 8 months ago

FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 10, 2025, 8:30 AM EST - 9 months ago

FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions

Nov 26, 2025, 8:30 AM EST - 9 months ago

FibroBiologics Announces Payoff of Outstanding Debt

Nov 25, 2025, 4:05 PM EST - 9 months ago

FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 24, 2025, 9:00 AM EST - 9 months ago

FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers$

Nov 20, 2025, 8:00 AM EST - 9 months ago

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Nov 19, 2025, 7:03 PM EST - 9 months ago

FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 19, 2025, 8:36 AM EST - 9 months ago

FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 31, 2025, 4:30 PM EDT - 10 months ago

FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 4:00 PM EDT - 10 months ago

FibroBiologics Earnings release: Q3 2025

Oct 31, 2025, 4:00 PM EDT - 10 months ago

FibroBiologics Quarterly report: Q3 2025

Oct 24, 2025, 8:30 AM EDT - 10 months ago

FibroBiologics to Present at Bio-Europe 2025

Oct 14, 2025, 8:30 AM EDT - 11 months ago

FibroBiologics to Present at the 2025 ThinkEquity Conference

ShangVXO Aug. 19 at 8:10 AM

0 · Reply

Casualtradess Aug. 17 at 4:05 PM

$FBLG Pipeline includes psoriasis, MS, disc degeneration🔥.

0 · Reply

Enoch120 Aug. 14 at 2:34 PM

$FBLG Way to go Armistice Capital! Hoping more tutes show up tooting their way to profits!

1 · Reply

rayankhader Aug. 14 at 2:18 PM

$KUST $VVOS $AGRZ $FBLG $WNW 🏦💰🛒🛍️🛒🛒🛍️🛒🛒🛍️🤷🏻‍♂️💎👀

0 · Reply

rayankhader Aug. 13 at 6:00 PM

$FBLG 🤷🏻‍♂️🛒🛍️🛍️🛍️

0 · Reply

swapo1 Aug. 13 at 5:37 PM

$FBLG next up

0 · Reply

rayankhader Aug. 13 at 5:21 PM

0 · Reply

rayankhader Aug. 13 at 5:05 PM

$INHD on fireeeeeeeeeeee 🏦🏦🏦🏦🏦🏦🏦 $WNW $VVOS $FBLG they will run hard 🤷🏻‍♂️💎🛒🛒💎💎💎💎💰🛍️🛍️💰💰🛒🏦💎💎💎

0 · Reply

STACKD0E Aug. 13 at 4:41 PM

$BGDE $QMLS $FBLG $RNXT 🙃✨️

0 · Reply

rayankhader Aug. 13 at 3:39 PM

$FBLG the big run coming

1 · Reply

Enoch120 Aug. 13 at 12:24 PM

$FBLG Institutional Q2 13F reports are starting to come in. So far Cascade Financial Partners are in the lead with an increase of purchases totaling 92,400 shares which gives them a total of 108,828 shares held. SEC reporting deadline is the 15th so more tutes's purchases and sales results coming.

0 · Reply

rayankhader Aug. 12 at 6:20 PM

$FBLG we will run soon

0 · Reply

rayankhader Aug. 11 at 2:35 PM

$FBLG 🛒👀👀👀

0 · Reply

_Christ_is_King_ Aug. 11 at 1:03 PM

$FBLG https://ir.fibrobiologics.com/news-events/press-releases/detail/131/fibrobiologics-granted-u-s-patent-covering-the-use-of-fibroblasts-to-enhance-survival-and-function-of-transplanted-insulin-producing-islets

0 · Reply

STACKD0E Aug. 11 at 12:53 PM

👁 $BGDE $QMLS $FBLG $RNXT

0 · Reply

AlertsAndNews Aug. 11 at 12:32 PM

$FBLG patent headline here as well. FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

0 · Reply